The regulatory action clears a pathway for future manufacturers to bring noise-canceling incubator systems to market through a less burdensome route.
The US Food and Drug Administration has established a formal regulatory category for active noise attenuation systems used inside infant incubators to potentially help prevent hearing loss, publishing a final order in the Federal Register that classifies the devices as Class II with special controls. The order took effect upon publication on July 27, 2026, and adds a new section — 21 CFR 880.5405 — to the code governing general hospital devices.
The classification does not introduce a new product to the market. Rather, it establishes a defined regulatory pathway and a set of mandatory performance and labeling requirements that future manufacturers must meet before bringing similar systems to clearance. Manufacturers may now pursue premarket notification under section 510(k) rather than the more burdensome premarket approval process typically required for Class III devices.
Regulatory History
The classification traces back to a De Novo request submitted by Invictus Medical Inc., a San Antonio-based company, on July 25, 2022, for its Neoasis device. FDA issued its classification order on June 16, 2023. The July 2026 Federal Register publication represents the separate administrative step that writes the decision into the Code of Federal Regulations, allowing the Neoasis to serve as a predicate for future substantially equivalent devices.
Read About What Kickstarted This:
The De Novo pathway exists to address a structural feature of US device law: any device not in commercial distribution before May 28, 1976, is automatically placed in Class III by operation of law, regardless of its actual risk profile. De Novo classification allows FDA to move a novel but lower-risk device to Class I or Class II. FDA stated in the order that the action would enhance patient access to beneficial innovation “in part by reducing regulatory burdens.”
The Device and the Clinical Problem It Addresses
FDA defines the device type as a system that captures environmental noise and outputs noise-canceling acoustic sound waves to reduce noise levels inside infant incubators in a healthcare setting. The technology applies the same active noise cancellation principle found in consumer headphones to the acoustic environment within a neonatal incubator.
The clinical rationale is grounded in published sound-level data from neonatal intensive care units. The American Academy of Pediatrics recommends that NICU sound levels remain below 45 decibels. Documented measurements have repeatedly found real units exceeding that threshold throughout significant portions of the day, with alarms, ventilators, infusion pumps, air-handling systems, and staff conversation all contributing to ambient noise. The incubator wall itself has been identified in some studies as both a reflector and a re-radiator of sound.
Research has associated sustained noise exposure with disrupted sleep and effects on weight gain in preterm infants, though those findings are largely observational. Whether active noise cancellation produces measurable improvements in neurodevelopmental outcomes, hearing, or length of stay has not been established in clinical trials. The Hearing Review has previously covered related NICU hearing research and the effects of auditory environments on preterm infants.
Safety Requirements and Special Controls
The order identifies three risks to health and the special controls required to address each.
Hearing loss is identified as the primary risk, linked to two failure modes: a device that outputs excessive sound of its own, and a device that fails to attenuate environmental noise as claimed. FDA notes that a system marketed as protective but performing inadequately poses a genuine hazard if clinical staff relax other noise-control practices based on the assumption that the device is working.
To address this, manufacturers must conduct non-clinical performance testing under anticipated use conditions. Required testing includes verification and validation of critical acoustic parameters — including maximum device output — and attenuation performance validated across compatible incubator models and dimensions, across different infant positions and orientations, and with relevant noise sources and room configurations. Software validation, verification, and hazard analysis are also required, as are electrical safety and electromagnetic compatibility testing for electrical components.
Infection is the second identified risk, addressed through labeling requirements.
Adverse tissue reaction is the third, addressed by requiring demonstrated biocompatibility of any patient-contacting or user-contacting components.
Labeling must include instructions for infant placement, expected attenuation performance, warnings about the device’s potential maximum output, cleaning and disinfection methods, and identification of the specific incubator models with which the device is intended to be used. That last requirement carries direct clinical significance: a system validated on one incubator model cannot be assumed to perform equivalently on another.
Implications for Hearing Care Professionals
For audiologists and hearing care professionals who work within or consult to NICU programs, the classification signals that active noise attenuation for incubators now has a defined regulatory framework, which may encourage additional manufacturers to pursue 510(k) clearance for substantially equivalent systems in the coming years.
The classification is a regulatory determination that the device type can be made reasonably safe and effective for its stated purpose of reducing noise inside incubators. It is not an FDA finding that quieter incubators produce improved clinical outcomes. That question awaits larger-scale clinical trial evidence.
Many NICUs already employ evidence-based noise management strategies — including quiet hours, alarm threshold management, single-family room designs, and staff training — that do not depend on active noise attenuation technology. The new classification adds a potential technological complement to those existing approaches, subject to the performance and labeling requirements now codified in federal regulation.
